Restricted accessResearch articleFirst published online 2021-06
Epidemiology,Risk Factors,and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Hematologic Malignancy: A Retrospective Study from Central South China
To determine the epidemiology, risk factors, and prognosis of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bloodstream infections (BSIs) among hematology malignancy (HM) patients in China.
Method:
From January 2010 to June 2018, we retrospectively collected and analyzed the 449 HM patients with E. coli or K. pneumoniae BSIs from three leading hospitals in Hunan Province, China.
Results:
Two hundred four (45.4%) patients harbored ESBL-producing bacteremia. The proportion of ESBL-producing bacteremia increased significantly with the growth of the year, with a ratio of 34.47% in 2010–2014 to 54.7% in 2015–2018. Comparing with non-ESBL groups in HM patients, central venous catheter (odds ratio [OR] 1.717, p = 0.009), previous antibiotic exposure (OR 1.559, p = 0.035), and E. coli (OR 2.561, p ≤ 0.001) among ESBL groups were independent risk factors. No significant differences in 30-day mortality were tested in patients with BSI caused by ESBL-producing or non-ESBL-producing E. coli and K. pneumoniae (17.1% vs. 16.7%; p = 0. 893). The proportion of carbapenem used within 72 hours after the onset of bacteremia in two groups was high, which was routinely used as “last-resort drugs” in Gram-negative bacterial infections. Risk factors associated with 30-day mortality in HM patients with E. coli or K. pneumoniae bacteremia were myelodysplastic syndrome, incomplete remission of the disease, Multinational Association of Supportive Care in Cancer score <21, Pitt bacteremia score ≥4, Charlson comorbidity score >3, catheter insertion, use of vasopressors, and inappropriate antibiotics within 72 hours of BSI onset.
Conclusions:
The results of this study may provide some references for the whole process management of HM patients with BSIs.
Get full access to this article
View all access options for this article.
References
1.
PanaZ.D., and ZaoutisT.. 2018. Treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? F1000Res 7:F1000 Faculty Rev-1347.
2.
NorgaardM., LarssonH., PedersenG., SchonheyderH.C, and SorensenH.T.. 2006. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin. Microbiol. Infect. 12:217–223.
3.
TumbarelloM., SpanuT., CairaM., TrecarichiE.M, LaurentiL., MontuoriE., FianchiL., LeoneF., FaddaG., CaudaR., and PaganoL.. 2009. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn. Microbiol. Infect. Dis. 64:320–326.
4.
AttmanE., AittoniemiJ., SinisaloM., VuentoR., LyytikainenO., KarkiT., SyrjanenJ., and HuttunenR.. 2015. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital. Leuk. Lymphoma, 56:3370–3377.
5.
ChenC.Y., TsayW., TangJ.L, TienH.F, and ChenY.-C, ChangS.-C, and HsuehP.-R.. 2010. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol. Infect. 138:1044–1051.
6.
TrecarichiE.M., PaganoL., CandoniA., PastoreD., CattaneoC., FanciR., NosariA., CairaM., SpadeaA., BuscaA., VianelliN., TumbarelloM., and HeMabis Registry-Seifem GroupI.2015. 5bial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin. Microbiol. Infect. 21:337–343.
7.
TangY., ChengQ., YangQ., LiuJ., ZhangD., CaoW., LiuQ., ZhouT., ZengH., ZhouL., WangQ., WeiH., and LiX.. 2018. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection, 46:513–521.
8.
FairR.J., and TorY.. 2014. Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem. 6:25–64.
9.
ChenS.Z., LinK.N, XiaoM., LuoX.F, LiQ., RenJ.H, HuangR.Y, ChenM.M, AllyZ.Z, ChenT., YangJ.D, and HuJ.. 2017. Distribution and drug resistance of pathogens of blood stream infection in patients with hematological malignancies after chemotherapy. Zhonghua Xue Ye Xue Za Zhi, 38:951–955.
10.
KaraO., ZarakoluP., AsciogluS., EtgulS., UzB., BuyukasikY., and AkovaM.. 2015. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect. Dis. (Lond). 47:686–693.
HuF.-P., GuoY., ZhuD.-M, and HuangW.. 2017. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Chin. J. Infect. Chemother. 17:93–99.
14.
StewardsonA., FankhauserC., De AngelisG., RohnerP., SafranE., SchrenzelJ., PittetD., and HarbarthS.. 2013. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect. Control Hosp. Epidemiol. 34:133–143.
15.
Ben-ChetritE., EldaimM.A, Bar-MeirM., DodinM., and KatzD.E.. 2019. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia. Int. J. Antimicrob. Agents, 53:423–428.
16.
KangC.I., ChungD.R, KoK.S, PeckK.R, and SongJ.H.. 2012. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann. Hematol. 91:115–121.
17.
GudiolC., CalatayudL., Garcia-VidalC., Lora-TamayoJ., CisnalM., DuarteR., ArnanM., MarinM., CarratalaJ., and GudiolF.. 2010. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J. Antimicrob. Chemother. 65:333–341.
18.
KimS.H., KwonJ.C, ChoiS.M, LeeD.G, ParkS.H, ChoiJ.H, YooJ.H, ChoB.S, EomK.S, KimY.J, KimH.J, LeeS., MinC.K, ChoS.G, KimD.W, LeeJ.W, and MinW.S.. 2013. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann. Hematol. 92:533–541.
19.
XiaoT., WuZ., ShiQ., ZhangX., ZhouY., YuX., and XiaoY.. 2019. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J. Glob. Antimicrob. Resist. 17:147–156.
20.
TrecarichiE.M., TumbarelloM., SpanuT., CairaM., FianchiL., ChiusoloP., FaddaG., LeoneG., CaudaR., and PaganoL.. 2009. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J. Infect. 58:299–307.
21.
CaiJ., ChengQ., ShenY., GuD., FangY., ChanE.W, and ChenS.. 2017. Genetic and functional characterization of blaCTX-M-199, a novel tazobactam and sulbactam resistance-encoding gene located in a conjugative mcr-1-bearing IncI2 plasmid. Antimicrob. Agents Chemother. 61:e00562-17.
22.
Cornejo-JuarezP., Perez-JimenezC., Silva-SanchezJ., Velazquez-AcostaC., Gonzalez-LaraF., Reyna-FloresF., Sanchez-PerezA., and Volkow-FernandezP.. 2012. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum beta-lactamase bloodstream infection in hematological malignancies. PLoS One, 7:e35780.
23.
KimY.J., JungS.M, KangJ., RyooS.M, SohnC.H, SeoD.W, LimK.S, HuhJ.W, KimS.H, and KimW.Y.. 2019. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia. Intern. Emerg. Med. 14:433–440.
24.
CharlsonM., SzatrowskiT.P, PetersonJ., and GoldJ.. 1994. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47:1245–1251.
25.
FlowersC.R., SeidenfeldJ., BowE.J, KartenC., GleasonC., HawleyD.K, KudererN.M, LangstonA.A, MarrK.A, RolstonK.V, and RamseyS.D.. 2013. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 31:794–810.
26.
ChowJ.W., and YuV.L.. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int. J. Antimicrob. Agents, 11:7–12.
27.
GarnerJ.S., JarvisW.R, EmoriT.G, HoranT.C, and HughesJ.M.. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control, 16:128–140.
McDanelJ., SchweizerM., CrabbV., NelsonR., SamoreM., KhaderK., BlevinsA.E, DiekemaD., ChiangH.Y, NairR., and PerencevichE.. 2017. Incidence of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review. Infect. Control Hosp. Epidemiol. 38:1209–1215.
30.
De AngelisG., FioriB., MenchinelliG., D'InzeoT., LiottiF.M, MorandottiG.A, SanguinettiM., PosteraroB., and SpanuT.. 2018. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015). Eur. J. Clin. Microbiol. Infect. Dis. 37:1627–1636.
31.
AlevizakosM., GaitanidisA., AndreatosN., ArunachalamK., FlokasM.E, and MylonakisE.. 2017. Bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis. Int. J. Antimicrob. Agents, 50:657–663.
32.
van LoonK., Voor in ‘t HoltA.F, and VosaM.C.. 2018. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 62:e01730-17.
33.
CantonR., AkovaM., CarmeliY., GiskeC.G, GlupczynskiY., GniadkowskiM., LivermoreD.M, MiriagouV., NaasT., RossoliniG.M, SamuelsenO., SeifertH., WoodfordN., NordmannP., and European Network on Carbapenemases. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18:413–431.
34.
JolivetS., VaillantL., PoncinT., LolomI., GaudonnetY., RondinaudE., BendjelloulG., LomontA., LucetJ.-C, and Armand-LefèvreL.. 2018. Prevalence of carriage of extended-spectrum β-lactamase-producing Enterobacteria and associated factors in a French hospital. Clin. Microbiol. Infect. 24:1311–1314.
35.
HanS.B., JungS.W, BaeE.Y, LeeJ.W, LeeD.G, ChungN.G, JeongD.C, ChoB., KangJ.H, KimH.K, and ParkY.J.. 2015. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb. Drug Resist. 21:244–251.
36.
RussoA., FalconeM., Gutierrez-GutierrezB., CalboE., AlmiranteB., VialeP.L, OliverA., Ruiz-GarbajosaP., GaschO., GozaloM., PitoutJ., AkovaM., PenaC., CisnerosJ.M, Hernandez-TorresA., FarcomeniA., PrimN., OriguenJ., BouG., TacconelliE., TumbarelloM., HamprechtA., KaraiskosI., de la CalleC., PerezF., SchwaberM.J, BermejoJ., LowmanW., HsuehP.R, Mora-RilloM., Rodriguez-GomezJ., SouliM., BonomoR.A, PatersonD.L, CarmeliY., PascualA., Rodriguez-BanoJ., VendittiM., and REIPI/ESGBIS/INCREMInvestigatorsENT. 2018. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int. J. Antimicrob. Agents, 52:577–585.
37.
KangC.I., WiY.M, KoK.S, ChungD.R, PeckK.R, LeeN.Y, and SongJ.H.. 2013. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand. J. Infect. Dis. 45:519–525.
38.
De RosaF.G., PaganiN., FossatiL., RavioloS., ComettoC., CavallerioP., ParlatoC., GuglielmiE., SerraR., and Di PerriG.. 2011. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection, 39:555–561.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
